Mohit Bansal
Stock Analyst at Wells Fargo
(4.59)
# 899
Out of 4,429 analysts
755
Total ratings
57.1%
Success rate
9.7%
Average return
Main Sectors:
Stocks Rated by Mohit Bansal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie | Maintained: Buy | $260 | $230.01 | +13.04% | 40 | Jun 21, 2026 | |
| HALO Halozyme Therapeutics | Rated: Hold | $75 | $68.99 | +8.71% | 26 | Jun 15, 2026 | |
| GILD Gilead Sciences | Rated: Buy | $165 | $124.87 | +32.14% | 62 | Jun 11, 2026 | |
| PFE Pfizer | Rated: Hold | $28 | $25.08 | +11.64% | 50 | Jun 11, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintained: Buy | $550 | $466.79 | +17.83% | 49 | Jun 11, 2026 | |
| TVTX Travere Therapeutics | Maintained: Buy | $50 → $65 | $55.11 | +17.95% | 22 | Jun 11, 2026 | |
| MRK Merck & Co. | Maintained: Buy | $145 | $115.48 | +25.56% | 51 | Jun 8, 2026 | |
| SMMT Summit Therapeutics | Rated: Buy | $30 | $14.28 | +110.08% | 11 | Jun 2, 2026 | |
| LLY Eli Lilly and Company | Maintained: Buy | $1,280 | $1,102.08 | +16.14% | 66 | May 27, 2026 | |
| BIIB Biogen | Maintained: Buy | $250 | $199.71 | +25.18% | 52 | May 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $60 | $54.70 | +9.69% | 41 | May 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $140 → $140 | $90.19 | +55.23% | 10 | May 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $75 | $55.90 | +34.17% | 25 | May 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $825 → $700 | $612.50 | +14.29% | 65 | May 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $250 → $265 | $225.92 | +17.30% | 17 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $5 | $3.82 | +30.89% | 16 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $375 → $390 | $344.72 | +13.14% | 47 | Apr 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $13 | $6.17 | +110.70% | 1 | Apr 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $55 | $25.37 | +116.79% | 15 | Mar 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $180 → $175 | $161.62 | +8.28% | 31 | Feb 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $4 → $8 | $1.31 | +510.69% | 3 | Dec 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $70 | $38.43 | +82.15% | 7 | Nov 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $47 | $54.79 | -14.22% | 13 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $95 | $82.00 | n/a | 1 | Jul 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $30 → $14 | $23.19 | n/a | 2 | Jun 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $3 | $0.00001 | n/a | 1 | Jun 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $52 | $1.16 | n/a | 1 | Apr 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $15 → $75 | $18.28 | n/a | 3 | Mar 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $20 → $33 | $34.23 | n/a | 2 | Mar 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $25 → $27 | $1.48 | n/a | 6 | Feb 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $36 → $75 | $5.24 | n/a | 2 | Jan 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 → $5 | $0.0004 | n/a | 5 | Jan 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $75 → $65 | $35.10 | n/a | 5 | Dec 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $11 → $8.5 | $3.04 | n/a | 4 | Sep 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $8 → $5 | $0.0335 | n/a | 2 | Apr 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $21 | $9.35 | n/a | 1 | Jun 11, 2019 |
AbbVie
Jun 21, 2026
Maintained: Buy
Price Target: $260
Current: $230.01
Upside: +13.04%
Halozyme Therapeutics
Jun 15, 2026
Rated: Hold
Price Target: $75
Current: $68.99
Upside: +8.71%
Gilead Sciences
Jun 11, 2026
Rated: Buy
Price Target: $165
Current: $124.87
Upside: +32.14%
Pfizer
Jun 11, 2026
Rated: Hold
Price Target: $28
Current: $25.08
Upside: +11.64%
Vertex Pharmaceuticals
Jun 11, 2026
Maintained: Buy
Price Target: $550
Current: $466.79
Upside: +17.83%
Travere Therapeutics
Jun 11, 2026
Maintained: Buy
Price Target: $50 → $65
Current: $55.11
Upside: +17.95%
Merck & Co.
Jun 8, 2026
Maintained: Buy
Price Target: $145
Current: $115.48
Upside: +25.56%
Summit Therapeutics
Jun 2, 2026
Rated: Buy
Price Target: $30
Current: $14.28
Upside: +110.08%
Eli Lilly and Company
May 27, 2026
Maintained: Buy
Price Target: $1,280
Current: $1,102.08
Upside: +16.14%
Biogen
May 22, 2026
Maintained: Buy
Price Target: $250
Current: $199.71
Upside: +25.18%
May 22, 2026
Maintained: Hold
Price Target: $60
Current: $54.70
Upside: +9.69%
May 22, 2026
Maintained: Buy
Price Target: $140 → $140
Current: $90.19
Upside: +55.23%
May 21, 2026
Rated: Buy
Price Target: $75
Current: $55.90
Upside: +34.17%
May 18, 2026
Rated: Hold
Price Target: $825 → $700
Current: $612.50
Upside: +14.29%
May 6, 2026
Maintained: Buy
Price Target: $250 → $265
Current: $225.92
Upside: +17.30%
May 5, 2026
Maintained: Hold
Price Target: $5
Current: $3.82
Upside: +30.89%
Apr 2, 2026
Rated: Hold
Price Target: $375 → $390
Current: $344.72
Upside: +13.14%
Apr 1, 2026
Maintained: Buy
Price Target: $13
Current: $6.17
Upside: +110.70%
Mar 13, 2026
Maintained: Buy
Price Target: $55
Current: $25.37
Upside: +116.79%
Feb 13, 2026
Maintained: Buy
Price Target: $180 → $175
Current: $161.62
Upside: +8.28%
Dec 16, 2025
Maintained: Buy
Price Target: $4 → $8
Current: $1.31
Upside: +510.69%
Nov 26, 2025
Maintained: Buy
Price Target: $70
Current: $38.43
Upside: +82.15%
Aug 12, 2025
Maintained: Buy
Price Target: $47
Current: $54.79
Upside: -14.22%
Jul 2, 2021
Reiterated: Buy
Price Target: $95
Current: $82.00
Upside: n/a
Jun 29, 2021
Maintained: Buy
Price Target: $30 → $14
Current: $23.19
Upside: n/a
Jun 4, 2021
Initiated Coverage: Buy
Price Target: $3
Current: $0.00001
Upside: n/a
Apr 5, 2021
Initiated Coverage: Buy
Price Target: $52
Current: $1.16
Upside: n/a
Mar 26, 2021
Initiated Coverage: Buy
Price Target: $15 → $75
Current: $18.28
Upside: n/a
Mar 24, 2021
Maintained: Buy
Price Target: $20 → $33
Current: $34.23
Upside: n/a
Feb 25, 2021
Maintained: Buy
Price Target: $25 → $27
Current: $1.48
Upside: n/a
Jan 20, 2021
Maintained: Buy
Price Target: $36 → $75
Current: $5.24
Upside: n/a
Jan 5, 2021
Maintained: Buy
Price Target: $10 → $5
Current: $0.0004
Upside: n/a
Dec 23, 2020
Maintained: Buy
Price Target: $75 → $65
Current: $35.10
Upside: n/a
Sep 15, 2020
Maintained: Hold
Price Target: $11 → $8.5
Current: $3.04
Upside: n/a
Apr 27, 2020
Maintained: Buy
Price Target: $8 → $5
Current: $0.0335
Upside: n/a
Jun 11, 2019
Initiated Coverage: Buy
Price Target: $21
Current: $9.35
Upside: n/a